Best Biotech Stocks to Consider on April 27

best biotech stocks

The coronavirus pandemic has resulted in a major crisis in the markets over the past weeks, and many stocks across a range of sectors have recorded substantial declines during this period. However, one of the sectors that has emerged with a lot of promise in these times is the biotech space, and it could be a good time for investors to start tracking the best biotech stocks in the market. Due to the coronavirus pandemic, the biotech industry has come into sharp focus, and in such a situation, it is only natural for investors to hunt for the best biotech stocks in the market.

The biotech sector has emerged as one of the few sectors in the economy that has not experienced as much damage as many of the other sectors. Here is a quick look at four of the best biotech stocks that could be worth adding onto the watch lists.

Best Biotech Stocks to Buy: CRISPR Therapeutics (NASDAQ:CRSP)

best biotech stocks

One of the best biotech stocks to have emerged in recent days is that of CRISPR Therapeutics, and investors could do well to keep an eye on it. The company is a market leader in CRISPR technology, which uses a DNA segment that has repetitions of base sequences. It is a sufficiently important technology for the overall development of the biotech sector since it could well be the first step towards manufacturing customized medicines.

At this point in time, the company is aiming to create medicines that are specifically meant for different forms of cancers and other specific diseases. However, the promise of CRISPR lies in the fact that the technology can actually be used in a wide category of medicine. Over the past month, CRSP stock has gained 30%.

Best Biotech Stocks to Buy: Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma has also emerged as a promising option for investors who are looking to invest in the best biotech stocks. Acceleron stock has had a rollercoaster ride in 2020. One of its products was rejected by the FDA in September 2019, but soon after, the product, luspatercept, received FDA breakthrough therapy designation.

Another major positive for the company was the positive data from the Phase 2 clinical trial of its pulmonary arterial hypertension product. The data was released in January, creating a lot of positivity around Acceleron stock.

>> 3 Hot Casino Stocks Recover on Better Earnings Prospect

Investors soon piled on to the stock on the back of these developments. XLRN stock rallied by 135%. Over the past month, it has gained 38%.

Best Biotech Stocks to Buy: Neurocrine Biosciences (NASDAQ:NBIX)

Over the past quarter of a century, Neurocrine has been involved in discovering treatments for a range of psychological and neurological disorders. In turn, the company has also emerged as one of the best biotech stocks on the market.

At this point in time, the company provides treatments meant for tardive dyskinesia and endometriosis. It has other products in the pipeline as well. As a matter of fact, its promising product pipeline may have led to Biogen (NASDAQ:BIIB) to make Neurocrine an acquisition target. The company’s impressive pipeline and the presence of a revenue-generating product portfolio make it a compelling option for many investors. NBIX stock has gained 20% over the past month.

Featured image: DepositPhotos © Alex011973

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.